Incyte (INCY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Incyte (INCY) is Neutral.

The composite score behind that read is +0.15, weighing +0.21 of bullish evidence against -0.13 bearish.

Incyte last closed at $112.79, +0.04% on the session.

Against the IVW growth benchmark the position is -0.76% over the forecast window.

The read is built from 15 underlying insights — 9 bullish and 6 bearish.

Agreement across those insights is 60%.

2 graded predictions for INCY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Incyte in the 65th percentile on valuation and the 87th percentile on return on equity, where 100 is best.

Incyte is classified under Health Care / Biotechnology, with a market capitalisation of $22.85B.

StockMap tracks Incyte as the 14th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Incyte ranks 27th of 381 in the group, against a group median of -0.08.